We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vancenase AQ 84 mcg Double Strength

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vancenase AQ 84 mcg Double Strength

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Vancenase AQ 84 mcg Double Strength, a once-daily aqueous corticosteroid nasal spray for adults and children six years of age and over, has been approved by the FDA.

    Available by prescription, Vancenase AQ 84 mcg Double Strength is indicated for the relief of symptoms of allergic and non-allergic (vasomotor) rhinitis, including sneezing, runny nose, and nasal congestion. Vancenase AQ 84 mcg Double Strength is a concentrated form of Vancenase AQ, a twice-daily formulation. The new Vancenase AQ formulation delivers 84 mcg of beclomethasone dipropionate per dose (two metered sprays, once daily), twice the amount of medication released in the same dosage of Vancenase AQ.

    Clinical Results

    Clinical trials with Vancenase AQ 84 mcg Double Strength in subjects with seasonal allergic rhinitis showed that this concentrated, once-daily medication is as safe and effective in relieving the symptoms of allergic rhinitis as the original formulation. In a recent study of 194 subjects diagnosed with allergic rhinitis, Vancenase AQ 84 mcg Double Strength, administered once daily, significantly reduced nasal symptoms when compared with placebo. The incidence of side effects in subjects treated with Vancenase AQ 84 mcg Double Strength was similar to that found with placebo.

    Approval Date: 1996-06-01
    Date Created: 1996-06-28 12:00:00
    Company Name: Schering-Plough
    Back to Listings

    Upcoming Events

    • 09Dec

      The Age of eSource: Modernizing Clinical Trials

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Patient-phsyician-consultation

      Giving Patients Back Their Voice in Clinical Trials

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing